Sangamo BioSciences Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Janney Montgomery Scott Downgrades Sangamo BioSciences (SGMO) to Neutral
August 4, 2016 7:25 AM EDTJanney Montgomery Scott downgraded Sangamo BioSciences (NASDAQ: SGMO) from Buy to Neutral with a price target of $8.00 (from $15.00).
For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.
Shares of Sangamo BioSciences closed at $6.84 yesterday.
... MoreSangamo Biosciences (SGMO) Misses Q2 EPS by 14c
August 3, 2016 4:36 PM EDTSangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.38), $0.14 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $5.38 million.
Financial Guidance for 2016 The Company updates guidance as follows:
Cash and Investments: Sangamo... More